VTRS vs ALVO vs GRML Stock Comparison

Viatris, Alvotech and Greenland Mines Prices as of Oct 26, 2026 Peers: Industry group
VTRS Viatris Inc
$18.29 +2.6% 1M +76.7% 1Y
Market cap
$21.01B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
2.62%
Generic Drugs Healthcare
7 wins
ALVO Alvotech
$4.62 -19.7% 1M -45.0% 1Y
Market cap
$1.44B
P/E
–
Revenue (TTM)
$105.94M
Div. yield
–
Generic Drugs Healthcare
1 win
GRML Greenland Mines Ltd
$5.79 -60.5% 1M +929.2% 1Y
Market cap
$14.65M
P/E
–
Revenue (TTM)
—
Div. yield
–
Generic Drugs Healthcare
1 win

Head to Head

9 decided of 12

Viatris leads on 7 of the 12 questions below (Viatris 7, Alvotech 1, Greenland Mines 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVTRSALVOGRMLLeader
Larger companyMarket capitalisation $21.01B $1.44B $14.65M VTRS
Cheaper on earningsLower P/E, profitable companies only -51.8x -5.1x -0.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 7.0x — — –
Faster revenue growthRevenue growth, trailing twelve months +4.4% -74.3% — VTRS
More profitableNet margin, trailing twelve months -2.8% -248.0% — VTRS
Better return on capitalReturn on invested capital -0.2% 4.4% — ALVO
Less leveragedLower net debt / EBITDA 4.6x 13.1x — VTRS
Higher dividend yieldTrailing dividend yield 2.62% — — –
Better 1-year returnPrice return, last 12 months +76.7% -45.0% +929.2% GRML
Better 5-year returnAnnualised price return, 5 years +6.9%/yr -14.1%/yr — VTRS
Less volatileAnnualised volatility, 1 year 32.4% 81.8% 445.7% VTRS
Higher overall scoreMean of the five percentile scores vs peers 66/100 47/100 34/100 VTRS

Percentile Scorecard

VTRSALVOGRML

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVTRSALVOGRML
Valuation 93 #42 of 626 72 #178 of 626 13 #542 of 626
Growth 47 #318 of 604 35 #396 of 604 2 #590 of 604
Profitability 81 #106 of 555 68 #177 of 555 68 #179 of 555
Financial Health 23 #510 of 658 15 #557 of 658 78 #147 of 658
Shareholder Returns 87 #49 of 368 – 7 #342 of 368
Overall 66 47 34
  • VTRS ranked among 673 companies in Pharmaceuticals and Biotechnology
  • ALVO ranked among 673 companies in Pharmaceuticals and Biotechnology
  • GRML ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVTRSALVOGRMLSPY
1 month +2.6%-19.7%-60.5% -0.8%
3 months +3.7%+50.0%+2,947.4% +3.5%
6 months +23.5%+40.0%+1,129.8% +7.0%
Year to date +46.9%-9.9%+1,903.5% +12.2%
1 year +76.7%-45.0%+929.2% +13.0%
3 years +108.6%-48.6%-45.8% +86.3%
3 years, per year +27.8%-19.9%-18.5% +23.1%
5 years +39.6%-53.3%— +68.6%
5 years, per year +6.9%-14.1%— +11.0%
10 years -52.0%—— +258.0%
10 years, per year -7.1%—— +13.6%

Risk

MeasureVTRSALVOGRMLSPY
Volatility, 1Y 32.4%81.8%445.7% 12.7%
Downside volatility, 1Y 29.6%86.1%158.9% 12.7%
Beta vs S&P 500, 1Y 0.700.732.77 1.00
Return / volatility, 1Y 2.37-0.552.08 1.02
Max drawdown, 5Y -52.9%-82.6%-99.0% -25.4%
From 52-week high -2.0%-43.2%-61.1% -1.8%
52-week high $18.66$8.13$14.89 $779.14
52-week low $10.11$3.00$0.17 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVTRSALVOGRML
P/E now vs peer median -51.8xmedian 17.1x -5.1xmedian 17.1x -0.7xmedian 17.1x
P/S now vs peer median 1.4xmedian 8.8x 13.6xmedian 8.8x —median 8.8x
EV/EBITDA now vs peer median 12.3xmedian 17.1x 29.3xmedian 17.1x —median 17.1x
P/FCF now vs peer median 10.7xmedian 18.0x -5.5xmedian 18.0x -1.0xmedian 18.0x
P/B now vs peer median 1.5xmedian 2.1x -7.5xmedian 2.1x 0.3xmedian 2.1x
PEG now vs peer median 1.69median 0.31 -0.21median 0.31 0.01median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVTRSALVOGRML
Revenue $14.74B $105.94M –
Gross profit $5.13B $7.66M –
Operating income -$87.30M $47.54M -$18.67M
Net income -$410.70M -$179.60M -$21.77M
Free cash flow $1.95B -$261.39M -$14.22M
R&D $1.02B $46.37M $1.28M
EPS (diluted) $-0.35 $-0.90 $-8.60
Cash & equivalents $886.50M $142.80M $9.34M
Total debt $13.35B $1.31B $2.07M
Shares (diluted) 1.16B 291.34M 2.53M
Enterprise value $16.02B $1.01B -$19.22M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVTRSALVOGRML
P/E -51.8x -5.1x -0.7x
P/FCF 10.7x -5.5x -1.0x
P/Operating cash flow 9.0x -7.3x -1.0x
P/S 1.4x 13.6x –
P/B 1.5x -7.5x 0.3x
P/Tangible book 36.0x -4.3x 1.6x
EV/EBITDA 12.3x 29.3x –
EV/EBIT -383.4x 54.8x -0.3x
EV/Revenue 2.3x 24.6x –
EV/FCF 17.1x -10.0x -0.4x
EV/Operating cash flow 14.4x -13.1x -0.4x
PEG (3Y EPS CAGR) 1.69 -0.21 0.01

Growth

14 metrics
MetricVTRSALVOGRML
Revenue growth (1Y) 4.4% -74.3% –
Revenue CAGR (3Y) -1.9% 104.2% –
Gross profit growth (1Y) -0.7% -95.0% –
Gross profit CAGR (3Y) -6.0% 27.6% –
Operating income growth (1Y) 96.6% -13.3% -127.6%
Operating income CAGR (3Y) -27.6% 28.9% -166.2%
Net income growth (1Y) 88.2% -383.6% -91.7%
Net income CAGR (3Y) -30.5% 24.4% -125.4%
EPS growth (1Y) 88.1% -481.6% 48.6%
EPS CAGR (3Y) -30.6% 24.6% -48.2%
Operating cash flow growth (1Y) 12.9% -367.1% -158.2%
Operating cash flow CAGR (3Y) -3.0% 12.8% -236.9%
Free cash flow growth (1Y) 11.6% -113.0% -158.2%
Free cash flow CAGR (3Y) -3.6% 8.6% -236.9%

Profitability

14 metrics
MetricVTRSALVOGRML
Gross margin 34.8% 7.2% –
EBITDA margin 18.4% 83.9% –
Operating margin -0.6% 44.9% –
Pretax margin -4.5% -62.1% –
Net margin -2.8% -248.0% –
FCF margin 13.3% -246.7% –
Operating cash flow margin 15.8% -187.6% –
Return on equity -2.8% – -39.8%
Return on assets -1.1% -17.5% -34.9%
Return on invested capital -0.2% 4.4% –
Return on capital employed -0.3% 4.1% -30.5%
Asset turnover 0.4x 0.1x –
Cash conversion (OCF / net income) -5.7x 1.1x 0.7x
Stock comp / revenue 1.2% 8.7% –

Financial Health

11 metrics
MetricVTRSALVOGRML
Debt / assets 38.1% 82.3% 0.5%
Debt / equity 0.9x -6.8x 0.0x
Net debt / EBITDA 4.6x 13.1x –
Debt / FCF 6.8x -5.0x 0.0x
Liabilities / assets 59.3% 112.1% 10.9%
Equity / assets 40.7% -12.1% 89.1%
Interest coverage -0.2x 0.8x -2,872x
Current ratio 1.6x 1.6x 10.1x
Quick ratio 0.7x 1.1x 7.7x
Cash ratio 0.1x 0.4x 7.7x
Altman Z-score 1.13 -1.37 –

Shareholder Returns

7 metrics
MetricVTRSALVOGRML
Dividend yield 2.6% – –
Net buyback yield 1.4% – -49.5%
Shareholder yield 4.1% – -49.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVTRSALVOGRML
Forward P/E 7.0xFY2026 – –
EPS, next fiscal year $2.62FY2026 $-0.02FY2026 –
EPS growth, next FY +11.5%FY2026 – –
EPS growth, the year after -1.9% – –
Revenue, next fiscal year $15.31BFY2026 $588.58MFY2026 –
Revenue growth, next FY +7.0%FY2026 -0.8%FY2026 –
Revenue growth, the year after -5.4% +22.3% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVTRSALVOGRML
Held by institutions 89.9% 14.7% 12.0%
Institutions holding 1,028 72 47
Change in shares held, QoQ +5.6% +152.4% +96.3%
Institutions buying 486 44 34
Institutions selling 318 17 2
Buyers to sellers 1.53 2.59 17.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VTRSALVOGRML
VTRS 1.00 0.05 0.08
ALVO 0.05 1.00 0.21
GRML 0.08 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VTRS, ALVO and GRML?

Viatris (VTRS) is the largest by market capitalisation: Viatris (VTRS) $21.01B, Alvotech (ALVO) $1.44B, Greenland Mines (GRML) $14.65M.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Viatris (VTRS) +4.4%, Alvotech (ALVO) -74.3%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Viatris (VTRS) -2.8%, Alvotech (ALVO) -248.0%). On return on invested capital, Alvotech (ALVO) leads (Viatris (VTRS) -0.2%, Alvotech (ALVO) 4.4%).

Which stock has performed better?

Over the past year Greenland Mines (GRML) returned the most: Viatris (VTRS) +76.7%, Alvotech (ALVO) -45.0%, Greenland Mines (GRML) +929.2%. Over five years, Viatris (VTRS) compounded fastest (Viatris (VTRS) +6.9%/yr, Alvotech (ALVO) -14.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Viatris (VTRS) 2.62%. Alvotech (ALVO) and Greenland Mines (GRML) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Viatris (VTRS) 32.4%, Alvotech (ALVO) 81.8%, Greenland Mines (GRML) 445.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, VTRS, ALVO and GRML?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.